Randomized, open-labeled study evaluating the antiviral efficacy, safety, and tolerability of continuing lamivudine therapy or switching to entecavir in subjects with chronic hepatitis B who achieved undetectable HBV DNA.
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Entecavir (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- 17 Nov 2015 Primary endpoint has been met. (Serum hepatits B virus [HBV] DNA 60 IU/mL while on randomized therapy), as per results published in the Journal of Gastroenterology and Hepatology.
- 17 Nov 2015 Results published in the Journal of Gastroenterology and Hepatology
- 07 May 2012 Actual patient number is 72 according to ClinicalTrials.gov.(NCT00625339).